Synergistic Antiproliferative Effect of Linagliptin-Metformin Combination on the Growth of Hela Cancer Cell Line
DOI:
https://doi.org/10.30683/1929-2279.2025.14.02Keywords:
Cervical cancer cell line, Hela cell line, MTT assay, Metformin, Linagliptin, Combination index, Dose reduction indexAbstract
This in-vitro study explores the cytotoxic properties of the linagliptin-metformin combination on cervical cancer cells and examines the synergistic interaction between the two drugs. An MTT assay was used to explore the anti-cancer effects of the linagliptin-metformin mixture on a cervical cancer cell line (HeLa cell line) across 24 and 72-hour incubation periods. The concentrations of metformin, linagliptin, and their combination ranged from 0.1 to 1000 µg/ml. while the concentrations in the mixture were kept at fifty percentage of the individually used drug. The study included an estimated combination index value (CI) and the dosage reduction index (DRI) to ascertain the possibility of a synergistic effect between combined drugs and mixture safety. study finding exhibited that all studied drugs- metformin, linagliptin, and their combined mixture- inhibited the growth of cervical cancer cells with a superior efficacy of the mixture over individual drugs. Inhibition patterns of the drugs were directly proportional to the drug's concentration and the incubation time. The combination index finding revealed that the mixture's cytotoxic effect of metformin and linagliptin was synergistic. The dose reduction index value revealed that lower drug concentrations were required in the combination mixture than when used individually indicating a greater cytotoxic potential of the mixture. The study findings of MTT, CI, and DRI indicate that the mixture is an effective, safer, and promising anticancer therapy for cervical cancer.
Conclusion: This study explores the cytotoxic potential of metformin and linagliptin individually and in combination. The greater cytotoxic potential of the drugs in combination highlights their lower effective concentrations, paving the way for further research on using these drugs for effective cancer treatment.
References
Allanson ER, Schmeler KM. Preventing cervical cancer globally: are we making progress? Cancer Prevention Research 2021; 14(12): 1055-60. DOI: https://doi.org/10.1158/1940-6207.CAPR-21-0016
Vijay A, Sona V, Radha A, Moorthi PV. A review on advancement perspectives in cervical cancer. Research Journal of Pharmacy and Technology 2017; 10(12): 4410-4. DOI: https://doi.org/10.5958/0974-360X.2017.00813.7
Nguyen DTN, Simms KT, Keane A, Mola G, Bolnga JW, Kuk J, et al. Towards the elimination of cervical cancer in low-income and lower-middle-income countries: modelled evaluation of the effectiveness and cost-effectiveness of point-of-care HPV self-collected screening and treatment in Papua New Guinea. BMJ global health 2022; 7(3): e007380. DOI: https://doi.org/10.1136/bmjgh-2021-007380
Allanson ER, Schmeler KM. Cervical cancer prevention in low-and middle-income countries. Clinical obstetrics and gynecology 2021; 64(3): 501-18. DOI: https://doi.org/10.1097/GRF.0000000000000629
Zhu G, Xiong Z, Chen W, Zhu Z, Wang W. Identification of key biomarkers and related immune cell infiltration in cervical cancer tissue based on bioinformatics analysis. Scientific reports 2023; 13(1): 10121. DOI: https://doi.org/10.1038/s41598-023-37346-z
Sheng B, Yao D, Du X, Chen D, Zhou L. Establishment and validation of a risk prediction model for high-grade cervical lesions. European Journal of Obstetrics & Gynecology and Reproductive Biology 2023; 281: 1-6. DOI: https://doi.org/10.1016/j.ejogrb.2022.12.005
Said AM, Abdulla KN, Ahmed NH, Yasin YS. Antiproliferative Impact of Linagliptin on the Cervical Cancer Cell Line. Asian Pacific Journal of Cancer Prevention: APJCP 2024; 25(9): 3293. DOI: https://doi.org/10.31557/APJCP.2024.25.9.3293
Abdulla KN, Aljebori S, Dh H, Mohson KI, Sabah Rasoul N, Mahdi MA. Risk factors for cervical cancer in Iraqi women. Libri Oncologici: Croatian Journal of Oncology 2023; 51(2-3): 59-64. DOI: https://doi.org/10.20471/LO.2023.51.02-03.09
Abdulla KN, Khashman BM, Alheshimi SJ, Oudah AA. The Status of Her2 Expression in a Group of Iraqi Women with Cervical Carcinoma. Indian Journal of Public Health Research & Development 2019; 10(9). DOI: https://doi.org/10.5958/0976-5506.2019.02589.0
Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler J, Wesley C, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology. 1999; 17(5): 1339. DOI: https://doi.org/10.1200/JCO.1999.17.5.1339
Eifel P, Winter K, Morris M, Levenback C, Grigsby P, Stevens R, et al. Pelvic radiation with concurrent chemotherapy versus pelvic and para-aortic radiation for high-risk cervical cancer: an update of RTOG 90–01. International Journal of Radiation Oncology, Biology, Physics 2002; 54(2): 1. DOI: https://doi.org/10.1016/S0360-3016(02)03056-0
Peters III WA, Liu P, Barrett RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of clinical oncology 2000; 18(8): 1606-13. DOI: https://doi.org/10.1200/JCO.2000.18.8.1606
Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New England Journal of Medicine. 1999; 340(15): 1154-61. DOI: https://doi.org/10.1056/NEJM199904153401503
Rose P. Chemoradiotherapy for cervical cancer. European Journal of Cancer 2002; 38(2): 270-8. DOI: https://doi.org/10.1016/S0959-8049(01)00352-5
Hade IM, Al-Khafaji AS, Lafta FM. Involvement of Total Antioxidant Activity and eNOS Gene rs1799983/rs2070744 Polymorphisms in Breast Carcinogenesis. Iraqi Journal of Science 2024: 1297-309. DOI: https://doi.org/10.24996/ijs.2024.65.3.11
Koh W-J, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 2019; 17(1): 64-84. DOI: https://doi.org/10.6004/jnccn.2019.0001
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, et al. NCCN guidelines insights: cervical cancer, version 1.2020: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network 2020; 18(6): 660-6. DOI: https://doi.org/10.6004/jnccn.2020.0027
Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. The lancet 2001; 358(9284): 781-6. DOI: https://doi.org/10.1016/S0140-6736(01)05965-7
Jumaa AH, Al Uboody WSH, Hady AM. Esomeprazole and Amygdalin combination cytotoxic effect on human cervical cancer cell line (Hela cancer cell line). Journal of Phar-maceutical Sciences and Research 2018; 10(9): 2236-41.
Jumaa AH, Jarad AS, Al Uboody WSH. The effect of esomeprazole on cell line human cervical cancer. Medico-Legal Update 2020; 20(1).
Hashim WS, Yasin YS, Jumaa AH, Al-Zuhairi MI, Abdulkareem AH. Physiological Scrutiny to Appraise a Flavonol Versus Statins. Biomedical and Pharmacology Journal 2023; 16(1): 289-93. DOI: https://doi.org/10.13005/bpj/2610
Jumaa AH, Abdulkareem AH, Yasin YS. The Cytotoxic Effect of Ciprofloxacin Laetrile Combination on Esophageal Cancer Cell Line. Asian Pacific Journal of Cancer Prevention: APJCP 2024; 25(4): 1433. DOI: https://doi.org/10.31557/APJCP.2024.25.4.1433
Chen Y-H, Wang P-H, Chen P-N, Yang S-F, Hsiao Y-H. Molecular and cellular mechanisms of metformin in cervical cancer. Cancers 2021; 13(11): 2545. DOI: https://doi.org/10.3390/cancers13112545
Shi B, Hu X, He H, Fang W. Metformin suppresses breast cancer growth via inhibition of cyclooxygenase-2. Oncology Letters 2021; 22(2): 1-14. DOI: https://doi.org/10.3892/ol.2021.12876
Jarad A. Diabetic wound healing enhancement by tadalafil 2020.
Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, et al. Low-dose metformin reprograms the tumor immune microenviron-ment in human esophageal cancer: results of a phase II clinical trial. Clinical Cancer Research 2020; 26(18): 4921-32. DOI: https://doi.org/10.1158/1078-0432.CCR-20-0113
Afzal MZ, Mercado RR, Shirai K. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma. Journal for immunotherapy of cancer 2018; 6: 1-10. DOI: https://doi.org/10.1186/s40425-018-0375-1
Tsuji S, Kudo U, Hatakeyama R, Shoda K, Nakamura S, Shimazawa M. Linagliptin decreased the tumor progression on glioblastoma model. Biochemical and biophysical research communications 2024; 711: 149897. DOI: https://doi.org/10.1016/j.bbrc.2024.149897
Yurttas AG, Dasci MF. Exploring the molecular mechanism of linagliptin in osteosarcoma cell lines for anti-cancer activity. Pathology-Research and Practice 2023; 248: 154640. DOI: https://doi.org/10.1016/j.prp.2023.154640
Yasin YS, Jumaa AH, Jabbar S, Abdulkareem AH. Effect of laetrile vinblastine combination on the proliferation of the hela cancer cell line. Asian Pacific Journal of Cancer Prevention: APJCP 2023; 24(12): 4329. DOI: https://doi.org/10.31557/APJCP.2023.24.12.4329
Rutledge S. What HeLa Cells Are You Using? Authorea Preprints 2023.
Jumaa AH. The cytotoxic effect of Vincristine-Amygdalin combination on human cervical cancer cell line (Hela cancer cell line). Iraqi Journal of Cancer and Medical Genetics 2016; 9(2). DOI: https://doi.org/10.29409/ijcmg.v9i2.187
Sharma AK, Singh AK, Waseem M, Kumar S. Animal cell culture. Clinical Biochemistry and Drug Development: Apple Academic Press; 2020. p. 7-31. DOI: https://doi.org/10.1201/9780367821470-2
Uysal O, Sevimli T, Sevimli M, Gunes S, Sariboyaci AE. Cell and tissue culture: the base of biotechnology. Omics tech-nologies and bio-engineering: Elsevier; 2018. p. 391-429. DOI: https://doi.org/10.1016/B978-0-12-804659-3.00017-8
Grela E, Kozłowska J, Grabowiecka A. Current methodology of MTT assay in bacteria–A review. Acta histochemica 2018; 120(4): 303-11. DOI: https://doi.org/10.1016/j.acthis.2018.03.007
Zhang Y, Qi D, Gao Y, Liang C, Zhang Y, Ma Z, et al. History of uses, phytochemistry, pharmacological activities, quality control and toxicity of the root of Stephania tetrandra S. Moore: A review. Journal of ethnopharmacology 2020; 260: 112995. DOI: https://doi.org/10.1016/j.jep.2020.112995
Bor T, Aljaloud SO, Gyawali R, Ibrahim SA. Antimicrobials from herbs, spices, and plants. Fruits, vegetables, and herbs: Elsevier; 2016. p. 551-78. DOI: https://doi.org/10.1016/B978-0-12-802972-5.00026-3
Meyer CT, Wooten DJ, Lopez CF, Quaranta V. Charting the fragmented landscape of drug synergy. Trends in pharmacological sciences 2020; 41(4): 266-80. DOI: https://doi.org/10.1016/j.tips.2020.01.011
Chou T-C. The combination index (CI< 1) as the definition of synergism and of synergy claims. Elsevier; 2018. p. 49-50. DOI: https://doi.org/10.1016/j.synres.2018.04.001
Cary NJSIIU. Statistical analysis system, User's guide. Statistical. Version 9 2012.
Sun Y, Liu Y, Ma X, Hu H. The influence of cell cycle regulation on chemotherapy. International journal of molecular sciences 2021; 22(13): 6923. DOI: https://doi.org/10.3390/ijms22136923
Li D, Yeung SCJ, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137(2): 482-8. DOI: https://doi.org/10.1053/j.gastro.2009.04.013
Sadeghi N, Abbruzzese JL, Yeung S-CJ, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clinical cancer research 2012; 18(10): 2905-12. DOI: https://doi.org/10.1158/1078-0432.CCR-11-2994
Lee JH, Kim TI. Type II diabetes, metformin use, and colorectal neoplasia: mechanisms of action and implications for future research. Current Colorectal Cancer Reports 2014; 10: 105-13. DOI: https://doi.org/10.1007/s11888-013-0198-x
Meng F, Song L, Wang W. Metformin improves overall survival of colorectal cancer patients with diabetes: a meta‐analysis. Journal of Diabetes Research 2017; 2017(1): 5063239. DOI: https://doi.org/10.1155/2017/5063239
Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. The Lancet Oncology 2016; 17(4): 475-83. DOI: https://doi.org/10.1016/S1470-2045(15)00565-3
Garrett C, Hassabo H, Bhadkamkar N, Wen S, Baladandayuthapani V, Kee B, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. British journal of cancer 2012; 106(8): 1374-8. DOI: https://doi.org/10.1038/bjc.2012.71
Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. International journal of cancer 2012; 131(3): 752-9. DOI: https://doi.org/10.1002/ijc.26421
Deng D, Yang Y, Tang X, Skrip L, Qiu J, Wang Y, et al. Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta‐analysis. Diabetes/metabolism research and reviews 2015; 31(6): 595-602. DOI: https://doi.org/10.1002/dmrr.2645
Hwang IC, Park SM, Shin D, Ahn HY, Rieken M, Shariat SF. Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention 2015; 16(2): 595-600. DOI: https://doi.org/10.7314/APJCP.2015.16.2.595
Lai S-W, Chen P-C, Liao K-F, Muo C-H, Lin C-C, Sung F-C. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Official journal of the American College of Gastroenterology| ACG 2012; 107(1): 46-52. DOI: https://doi.org/10.1038/ajg.2011.384
Chen H-P, Shieh J-J, Chang C-C, Chen T-T, Lin J-T, Wu M-S, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 2013; 62(4): 606-15. DOI: https://doi.org/10.1136/gutjnl-2011-301708
Logie L, Harthill J, Patel K, Bacon S, Hamilton DL, Macrae K, et al. Cellular responses to the metal-binding properties of metformin. Diabetes 2012; 61(6): 1423-33. DOI: https://doi.org/10.2337/db11-0961
Ouyang J, Parakhia RA, Ochs RS. Metformin activates AMP kinase through inhibition of AMP deaminase. Journal of Biological Chemistry 2011; 286(1): 1-11. DOI: https://doi.org/10.1074/jbc.M110.121806
Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer research 2007; 67(14): 6745-52. DOI: https://doi.org/10.1158/0008-5472.CAN-06-4447
Hawley SA, Ford RJ, Smith BK, Gowans GJ, Mancini SJ, Pitt RD, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 2016; 65(9): 2784-94. DOI: https://doi.org/10.2337/db16-0058
Hamarsheh Sa, Groß O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nature communications 2020; 11(1): 5439. DOI: https://doi.org/10.1038/s41467-020-19288-6
Li Y, Li Y, Li D, Li K, Quan Z, Wang Z, et al. Repositioning of hypoglycemic drug linagliptin for cancer treatment. Frontiers in pharmacology 2020; 11: 187. DOI: https://doi.org/10.3389/fphar.2020.00187
Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, dos Santos GA, Falcao RP, Rego EM. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leukemia research 2011; 35(2): 260-4. DOI: https://doi.org/10.1016/j.leukres.2010.07.034
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
